Three biomed startups — Cerevast Medical, Novokera, and Aegeria Soft Tissue — merged to form a new entity called Longevity Biomedical.  The new company is looking to raise $30M through a public listing via a SPAC merger with blank cheque company Denali Capital Acquisition Corp, formed by investment bank U.S. Tiger Securities.  More: The firm expects to raise an additional $30M through PIPE funding.  The Bothell, Wash.-based firm will use the proceeds to accelerate clinical trials and preclinical studies of therapeutics and grow its team size.  Longevity is poised to achieve a $236.2M valuation at the public listing.  With the merger, Longevity's product portfolio includes stroke and retinal vein occlusion treatment, soft-tissue reconstruction, and a preclinical product for corneal blindness.  Cerevast's CEO, Bradford Zakes, will lead the newly merged entity as its CEO and president.  Zakes was formerly the CEO at ImaRx Therapeutics, which was acquired by Cerevast.